Showing results (131-140 of 439) with videos related to
Sort By:
Pageof 44
Journal of Clinical Medicine|October 16, 2025
Increased Rate of Anemia and Discontinuation in Older Patients with Myelofibrosis Treated with RuxolitinibAlessandro Laganà, Emilia Scalzulli, Ida Carmosino, et al.Clinical Lymphoma, Myeloma & Leukemia|May 20, 2026
Frontline Nilotinib Versus Dasatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Propensity Score Analysis Based on Agenzia Italiana del Farmaco Monitoring RegistriesMassimo Breccia, Simone Celant, Fabrizio Pane, et al.Annals of Hematology|May 29, 2018
Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular eventsMatteo Molica, Emilia Scalzulli, Gioia Colafigli, et al.European Journal of Haematology|June 30, 2025
Treatment Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML): Analysis of Predictive Factors and Novel Baseline Scoring System to Predict Molecular RelapseAlessandro Laganà, Emilia Scalzulli, Ida Carmosino, et al.Journal of Geriatric Oncology|April 11, 2020
Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task forceHeidi D Klepin, Nina Rosa Neuendorff, Richard A Larson, et al.Frontiers in Oncology|June 26, 2020
Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid LeukemiaMario Annunziata, Massimiliano Bonifacio, Massimo Breccia, et al.Expert Opinion on Emerging Drugs|May 31, 2023
Systemic mastocytosis: 2023 update on diagnosis and management in adultsAlessandro Costa, Emilia Scalzulli, Ida Carmosino, et al.European Journal of Clinical Investigation|November 12, 2020
Outcomes of long-term anticoagulant treatment for the secondary prophylaxis of splanchnic venous thrombosisAlessandra Serrao, Manuela Merli, Benedetta Lucani, et al.Leukemia Research|August 11, 2007
Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinibMassimo Breccia, Laura Cannella, Daniela Diverio, et al.Clinical Lymphoma, Myeloma & Leukemia|October 26, 2025
SOHO State of the Art Updates and Next Questions | Choosing the Best Frontline BCR::ABL1 Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia-How to Define the Treatment Value?Fadi G Haddad, Elias Jabbour, Massimo Breccia, et al.Pageof 44